Revenue during the quarter grew 13.43 percent to $3,057.10 million from $2,695.20 million in the previous year period. Gross margin for the quarter contracted 682 basis points over the previous year period to 41.98 percent. Operating margin for the quarter stood at negative 4.28 percent as compared to a positive 22.30 percent for the previous year period.

Operating loss for the quarter was $130.70 million, compared with an operating income of $601.10 million in the previous year period.

However, the adjusted operating income for the quarter stood at $953.40 million compared to $911.90 million in the prior year period. At the same time, adjusted operating margin contracted 265 basis points in the quarter to 31.19 percent from 33.83 percent in the last year period.

Mylan chief executive officer Heather Bresch commented, "Our third quarter results were consistent with the full year guidance we provided a few weeks ago. During the quarter, we reported strong performance across our European and Rest of World regions, as well as solid performance across our North American region despite challenging year-over-year comparisons due to the significant contribution from new products in last year's third quarter. In our Specialty segment, while EpiPen® Auto-Injector scripts grew quarter-over-quarter, volumes were down due to the lack of wholesaler purchases in the quarter in anticipation of our upcoming generic launch.

For financial year 2016, the company forecasts diluted earnings per share to be in the range of $4.70 to $4.90 on adjusted basis.